Kaposi sarcoma

Meet the patient — the purple patch on the hard palate

A 34-year-old man with newly diagnosed HIV notices a painless purple patch on his hard palate that has darkened over a month, alongside a few similar bruises on his nose and earlobes that do not resolve. The patch does not blanch. This is not a traumatic bruise — it is epidemic Kaposi sarcoma, an AIDS-defining illness, and the hard palate is its single most characteristic oral site.^[1]

Two questions decide his next month: what is the immunosuppressive driver? (here, untreated HIV) and is the disease cutaneous-only or visceral? Restore immune control of HHV-8 — start ART — and the lesions may regress on their own; miss visceral disease and the patient may bleed from his gut or drown in his lungs. The virus is the same in every variant; what changes is whose immunity failed.^[1][3]

HHV-8 plus failing immunity — the single sentence that frames the topic

Despite the name "sarcoma," KS is best understood as a low-grade angioproliferative neoplasm of lymphatic endothelium rather than a true soft-tissue sarcoma. The proliferating spindle cell is an endothelial cell — often of lymphatic lineage, expressing PROX1, LYVE-1, and podoplanin — reprogrammed by latent HHV-8 infection.^[1]

The defining fact that earns viva marks: HHV-8 is necessary but not sufficient. The virus infects most carriers silently; clinical KS emerges only when host T-cell surveillance collapses — through HIV, transplant drugs, or simple ageing. The four variants differ only in who is immunosuppressed; the lesion, the histology, and the virus are identical, which is why treatment targets the cause first.^[1][5]

First described by the Hungarian dermatologist Moritz Kaposi in 1872 as an "idiopathic multiple pigmented sarcoma of the skin," the disease was a curiosity of elderly Mediterranean men for a century. The HIV epidemic made it a global priority; in 1994 Chang and Moore identified HHV-8 in KS lesions, and the epidemic form became an AIDS-defining illness and the commonest tumour in people living with HIV.^[1]

The four variants — same virus, four faces

The epidemiologic variants are clinically and prognostically distinct but histologically indistinguishable, and mastering the four-type framework is the single most tested fact in this topic.^[1]

Morphologic stages — patch, plaque, nodule

Beyond the epidemiologic variants, cutaneous KS evolves through morphologic stages that mirror histologic progression. Examiners use this ladder to test recognition of early disease.^[6]

Why HHV-8 is necessary but not sufficient — the oncogenic cascade

The pathogenesis is a paradigm of virus-driven oncogenesis gated by host immunity, and each step is both a viva question and a therapeutic target. Learn the cascade in order.^[1][4]

HHV-8 (KSHV) is a gamma-2-herpesvirus of the Rhadinovirus genus whose double-stranded DNA genome has pirated a remarkable array of human cellular homologue genes. After infecting endothelial cells it establishes latency in most (driving the spindle-cell proliferative phenotype) while a minority support lytic replication (supplying paracrine angiogenic and inflammatory signals).^[1][5]

^[1]

The same virus causes two other HHV-8-associated disorders examiners may pair with KS in a viva: primary effusion lymphoma (PEL), a B-cell lymphoma presenting as a malignant effusion in body cavities, and multicentric Castleman disease (MCD), especially its plasma-cell variant in HIV. A patient may carry more than one HHV-8-associated diagnosis at once, particularly in advanced HIV.^[2]

The clinical picture — the lesion, the distribution, the viscera

The lesions themselves are stereotyped; what changes between variants is where they appear and how fast they progress. KS begins as a pink, red, purple, or brown macule or patch, oval and aligned with skin lines, evolving into a raised plaque and eventually a dome-shaped nodule that may ulcerate or bleed.^[1][6]

The distribution by variant is the discriminator examiners probe:^[1][3]

• Classic KS — slowly progressive purple-brown patches, plaques, and nodules on the lower legs, ankles, and feet, often asymmetric, frequently complicated by lymphoedema; visceral involvement is uncommon and late.
• Endemic KS — more aggressive cutaneous disease with visceral and nodal involvement common even in HIV-negative patients; the lymphadenopathic variant hits prepubertal children.
• Iatrogenic KS — appears months to years after transplantation, often the first sign that immunosuppression is excessive; skin with or without viscera.
• Epidemic KS — widespread lesions on the face (nose, ears), trunk, genitals, and oral mucosa, often rapidly progressive, with visceral involvement frequent.^[1]

Mucosal involvement is most characteristic of the epidemic form. The hard palate is the single most common oral site and is virtually pathognomonic in an HIV-positive patient — a purple, red, or bluish patch, plaque, or nodule that does not blanch. Other oral sites include the gums, soft palate, and tongue.^[1]

Visceral KS affects the gastrointestinal tract, the respiratory tract, and the lymph nodes, and less commonly the liver and spleen:^[3][6]

• Gastrointestinal — the commonest visceral site; occult or overt bleeding, abdominal pain, diarrhoea, or obstruction, even when asymptomatic endoscopically.
• Pulmonary — dyspnoea, cough, wheeze, and haemoptysis; imaging shows lower-lobe-predominant interstitial or nodular infiltrates, pleural effusions, or endobronchial lesions. Pulmonary KS carries a worse prognosis.
• Lymph nodes and lymphatics — lymphadenopathy and lymphoedema disproportionate to the visible cutaneous burden, which can be painful, disfiguring, and refractory.^[1]

Dermoscopy is a bedside adjunct, not diagnostic — biopsy remains mandatory. The classical pattern is violaceous to bluish-reddish homogeneous areas traversed by small brownish globules reflecting hemosiderin, with a suggestive multicoloured "rainbow pattern" under polarised light that is not pathognomonic (it appears in melanoma too).^[6]

KS-IRIS — the paradoxical flare

A paradoxical worsening or new appearance of KS within weeks to months of starting ART, KS-IRIS is a T-cell-driven inflammatory reaction against HHV-8-infected cells as immunity recovers. Risk is highest with very low baseline CD4 (often under 50 to 100), high viral load, pre-existing subclinical KS, and a rapid CD4 rise.^[10]

The one rule that must not be broken: do not stop ART. Management is conservative — continue ART, treat opportunistic infections, and reserve systemic steroids and chemotherapy for severe or organ-threatening disease. Visceral IRIS-KS can be fatal, but the prognosis is generally favourable if ART is sustained.^[10]

Differential diagnosis — bacillary angiomatosis is the great mimic

The KS differential centres on vascular and pigmented lesions. The discriminator examiners want is the recognition that bacillary angiomatosis is the great mimic — and that it is treatable with antibiotics.^[1][6]

The decisive discriminator is always the skin biopsy with HHV-8 LANA immunostain: a LANA-positive spindle-cell vascular tumour with slit-like spaces and extravasated red cells is KS.^[1]

Investigations — biopsy, then stage and characterise

The skin biopsy is the diagnostic gold standard; serology and imaging stage the disease and characterise the immunosuppressive context.^[1][6]

^[1]

The ACTG TIS staging — three axes, one prognosis

KS is staged on three axes, each scored "good" as 0 and "poor" as 1. The framework examiners expect verbatim:^[8]

• T (Tumour) — T0 is disease confined to skin, lymph nodes, or minimal oral disease; T1 is tumour-associated oedema or ulceration, extensive oral KS, or visceral non-nodal disease.
• I (Immune) — I0 is a CD4 at least 150 cells per microlitre; I1 is a CD4 under 150.
• S (Systemic illness) — S0 is no HIV-related systemic illness with a Karnofsky of at least 70; S1 is systemic illness present (opportunistic infection or B symptoms) or a Karnofsky under 70.^[8]

Poor prognosis is defined as any one of T1, I1, or S1. In the post-ART era, CD4 carries less weight — many clinicians now stage primarily on tumour extent and symptoms.^[8]

Management — restore immune control first, then layer on local or systemic therapy

Definitive management is stratified by variant, extent, and immune context. The unifying principle is to restore immune control of HHV-8 wherever possible, then add local or systemic therapy for symptomatic, cosmetic, or visceral disease.^[1][3]

^[1]

Epidemic (HIV-associated) KS

^{[1] [1]}

Iatrogenic (transplant-associated) KS

The decisive move is to modify the immunosuppressive regimen before reaching for chemotherapy — regain immune control of HHV-8 while protecting the graft.^[1][9]

^[1]

Classic and endemic KS

Classic KS is indolent and rarely life-threatening; treatment is shaped by symptoms, cosmesis, and preference — observation for asymptomatic disease, radiotherapy as the workhorse for localised symptomatic or cosmetic disease on the lower legs, cryotherapy and intralesional vinblastine for a small number of lesions, and systemic therapy reserved for extensive, painful, lymphoedematous, or progressive disease.^[1]

Endemic KS is treated with the same modalities but its more aggressive course warrants earlier systemic therapy; in HIV-positive patients ART is first-line, and liposomal doxorubicin is standard for HIV-negative endemic disease with extensive or visceral involvement.^[1]

^[1]

Prognosis — the variant and the immune context decide it

Prognosis is dominated by the variant and the immune context, not by tumour bulk alone.^[1][3]

^[1]

Poor prognostic factors are visceral (T1) disease, low CD4 (under 150 to 200), high HIV viral load, systemic illness or opportunistic infection (S1), a Karnofsky under 70, and failure of immune restoration. The strongest single favourable factor in epidemic KS is sustained ART with viral suppression and CD4 recovery.^[3][8]

The trials that anchor practice

Two studies define the modern systemic standard, and an examiner expects both named.^[1][3]

^[1]

Regional deltas — global virus, regional drugs

The disease is global; the drugs and pathways are regional.^[3]

The mantra, and the memory device

^[1]

The mantra: HHV-8 plus failing immunity; treat the cause — ART or an mTOR switch — before you reach for chemotherapy.^[1][9]

Etymology for viva gold: Kaposi sarcoma honours Moritz Kaposi (born Moriz Kohn), the Hungarian dermatologist who described it in 1872. The virus was renamed KSHV when Chang and Moore found it in 1994, but the older HHV-8 persists in exams — both names are the same gamma-2-herpesvirus.^[1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the purple hard-palate patch in a man with HIV (answer)ShowHide

A 34-year-old with untreated HIV has a painless, non-blanching purple patch on his hard palate and a few similar bruises on his nose. What is the diagnosis, the confirmatory test, and the first treatment? Model: This is epidemic Kaposi sarcoma, an AIDS-defining illness — the hard palate is its single most characteristic oral site. Confirm with a skin or mucosal biopsy and HHV-8 LANA immunostain (spindle cells, slit-like vascular spaces, extravasated red cells, hemosiderin, and speckled nuclear LANA positivity), and test HIV with CD4 and viral load. The first treatment is to start ART — immune restoration alone produces partial or complete KS regression in 60 to 80 percent. Add local or systemic therapy for bulky, symptomatic, or visceral disease.^[1][3]

Stem 2 — KS in a renal-transplant recipient on tacrolimus (answer)ShowHide

A renal-transplant recipient develops purple-brown nodules on his leg two years post-transplant while on tacrolimus, mycophenolate, and prednisolone. Biopsy confirms KS. What is the first therapeutic move, and why? Model: The first move is to modify the immunosuppressive regimen — reduce immunosuppression to the lowest level compatible with graft survival and switch the calcineurin inhibitor (tacrolimus) to an mTOR inhibitor such as sirolimus. mTOR inhibitors have intrinsic anti-KS and anti-angiogenic activity, blocking the PI3K-Akt-mTOR axis HHV-8 exploits, and may regress KS while maintaining immunosuppression. Systemic chemotherapy is reserved for extensive or visceral disease not controlled by regimen modification, in close coordination with the transplant team.^[1][9]

Stem 3 — a KS flare three weeks after starting ART (answer)ShowHide

Three weeks after starting ART for advanced HIV, a patient's KS lesions multiply and new nodules appear, with fever and lymphadenopathy. The registrar wants to stop ART. What is the diagnosis, and what is the right call? Model: This is KS-associated immune reconstitution inflammatory syndrome (KS-IRIS) — a paradoxical flare as recovering T-cell immunity turns on HHV-8-infected cells, commonest when ART starts at a very low CD4 count. Do not stop ART. Continue it, treat any opportunistic infection, and reserve systemic steroids and chemotherapy for severe or organ-threatening disease. The prognosis is generally favourable if ART is sustained, though visceral IRIS-KS can be fatal and needs specialist input.^[10]

References10ShowHide

1. [1]Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma Nat Rev Dis Primers, 2019.PMID 30705286
2. [2]Carbone A, Borok M, Damania B, et al. Castleman disease Nat Rev Dis Primers, 2021.PMID 34824298
3. [3]Patel R, Lurain K, Yarchoan R, et al. Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies Expert Rev Anti Infect Ther, 2023.PMID 37578202
4. [4]Xiao Q, Liu Y, Li T, et al. Viral oncogenesis in cancer: from mechanisms to therapeutics Signal Transduct Target Ther, 2025.PMID 40350456
5. [5]Iftode N, Rădulescu MA, Aramă ȘS, et al. Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) - review Rom J Intern Med, 2020.PMID 32681788
6. [6]Radu O, Pantanowitz L. Kaposi sarcoma Arch Pathol Lab Med, 2013.PMID 23368874
7. [7]Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy J Clin Oncol, 1997.PMID 9053490
8. [8]Krown SE, Testa MA, Huang J, et al. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee J Clin Oncol, 1997.PMID 9294471
9. [9]Stallone G, Infante B, Grandaliano G, et al. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression Transpl Int, 2008.PMID 18498314
10. [10]Poizot-Martin I, Brégigeon S, Palich R, et al. Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma Cancers (Basel), 2022.PMID 35205734